Curated News
By: NewsRamp Editorial Staff
February 23, 2026

TransCode Unveils Novel Cancer Immunotherapy with Imaging Capability

Discuss on Substack
Original Source

TLDR

  • TransCode Therapeutics' novel immunotherapy strategy offers a competitive edge by targeting cancer cells precisely, potentially improving treatment efficacy and reducing side effects for patients.
  • The strategy uses a template-directed RIG-I agonist approach with miRNA-21 to activate immune responses in cancer cells, combined with TTX nanoparticles for targeted delivery and imaging.
  • This innovation could make the world better by advancing cancer treatment with fewer side effects, offering hope for improved quality of life and survival rates.
  • TransCode's research enables non-invasive imaging of drug delivery in cancer cells, merging immunotherapy with real-time monitoring for a fascinating breakthrough in oncology.

Impact - Why it Matters

This development represents a significant advancement in cancer treatment that could transform how metastatic cancers are managed. By combining targeted immunotherapy with non-invasive imaging, this approach addresses two critical challenges in oncology: reducing harmful side effects through tumor-specific targeting and enabling real-time monitoring of treatment effectiveness. For patients with advanced cancers, particularly those with metastatic disease, this technology offers hope for more precise, effective treatments with fewer complications. The ability to visualize drug delivery could revolutionize treatment protocols, allowing doctors to adjust therapies based on actual tumor response rather than generalized protocols. In the broader context of cancer research, this represents progress toward personalized medicine where treatments are tailored to individual tumor biology, potentially improving survival rates and quality of life for millions affected by cancer worldwide.

Summary

TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biotechnology company, has announced a significant scientific breakthrough with the publication of a manuscript in Molecular Imaging and Biology. The study details a novel tumor-selective immunotherapy strategy that activates RIG-I signaling within cancer cells while enabling non-invasive imaging of drug delivery. This innovative approach, developed in collaboration with Michigan State University researcher Dr. Anna Moore, utilizes a template-directed RIG-I agonist that leverages overexpressed oncogenic microRNAs such as miRNA-21 to drive intracellular immune activation while reducing off-target toxicity. The research highlights the potential clinical relevance of combining tumor-specific RNA templating with TransCode's proprietary TTX nanoparticle delivery platform, which is currently under clinical evaluation.

The company's lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode's broader portfolio includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The publication represents a crucial step forward in immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. For investors and stakeholders, the latest news and updates relating to RNAZ are available in the company's newsroom, while the full press release can be accessed through the provided link.

This announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on biotechnology, biomedical sciences, and life sciences developments. BioMedWire provides comprehensive distribution services including wire solutions, article syndication to thousands of outlets, enhanced press release features, social media distribution, and tailored corporate communications solutions. The platform serves both private and public companies seeking to reach investors, influencers, consumers, journalists, and the general public with breaking news and insightful content in the rapidly evolving biotech sector.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Unveils Novel Cancer Immunotherapy with Imaging Capability

blockchain registration record for this content.